hypoxia measurement for Prostate Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Prostate Cancerhypoxia measurement - Procedure
Eligibility
18+
Male
What conditions do you have?
Select

Study Summary

This trial is testing whether the hormone therapy Casodex can improve oxygen levels in the prostate, which may help treat the cancer.

Eligible Conditions
  • Prostate Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

4 Primary · 1 Secondary · Reporting Duration: 8 weeks

8 weeks
Correlate level of tumor oxygenation with PSA level
Correlate level of tumor oxygenation with hemoglobin level
Correlate level of tumor oxygenation with prostate volume
To determine the effect of neoadjuvant anti-androgen therapy on oxygenation of prostatic tumours
To study of the effect of neoadjuvant anti-androgen therapy on prostate tumour histopathology and gene expression, and correlation of these effects with changes in oxygenation.

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

hypoxia measurement
1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: hypoxia measurement · No Placebo Group · N/A

hypoxia measurement
Procedure
Experimental Group · 1 Intervention: hypoxia measurement · Intervention Types: Procedure

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 8 weeks

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,382 Previous Clinical Trials
473,445 Total Patients Enrolled
63 Trials studying Prostate Cancer
15,372 Patients Enrolled for Prostate Cancer
Princess Margaret Hospital, CanadaOTHER
114 Previous Clinical Trials
30,058 Total Patients Enrolled
8 Trials studying Prostate Cancer
1,516 Patients Enrolled for Prostate Cancer
Canadian Cancer Trials GroupNETWORK
114 Previous Clinical Trials
65,993 Total Patients Enrolled
10 Trials studying Prostate Cancer
6,825 Patients Enrolled for Prostate Cancer
Michael Milosevic, MDPrincipal InvestigatorPrincess Margaret Hospital, Canada
10 Previous Clinical Trials
1,118 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Male Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
substudy, will have blood drawn at study entry, within 3 weeks after completing radiotherapy, and at 3, 6, and 12 months after radiotherapy